Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
8.70
-0.08 (-0.91%)
Nov 21, 2024, 12:44 PM EST - Market open

Company Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.

The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.

In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications.

The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.

Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc.
Ocular Therapeutix logo
Country United States
Founded 2006
IPO Date Jul 25, 2014
Industry Biotechnology
Sector Healthcare
Employees 267
CEO Pravin Dugel

Contact Details

Address:
15 Crosby Drive
Bedford, Massachusetts 01730
United States
Phone 781 357 4000
Website ocutx.com

Stock Details

Ticker Symbol OCUL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001393434
CUSIP Number 67576A100
ISIN Number US67576A1007
SIC Code 2834

Key Executives

Name Position
Dr. Pravin U. Dugel M.D. Executive Chairman, President and Chief Executive Officer
Donald Notman Jr. Chief Financial Officer, Chief Operating Officer and Principal Accounting Officer
Dr. Jeffrey S. Heier M.D. Chief Scientific Officer
Dr. Peter K. Jarrett Ph.D. Chief Technology Officer
William S. Slattery Jr. Vice President of Investor Relations
William H. Ransone II Vice President of Global Sales and Marketing
Tracy Smith Vice President of Human Resources
Steve Meyers Chief Commercial Officer
Dr. Peter K. Kaiser M.D. Chief Development Officer
Sanjay Nayak MBBS, Ph.D. Chief Strategy Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 S-8 Securities to be offered to employees in employee benefit plans
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 16, 2024 144 Filing